Strengths and limitations
EVENTS, HIGH TRIGLYCERIDES
This work included comprehensive analyses of data in Chinese patients, which allowed for a more targeted evaluation of IPE's effectiveness and safety in this population. These data indicated that IPE was effective for the treatment of very high triglyceride condition in Chinese patients, and that it was well-tolerated. Furthermore, the study was able to identify an effective dosage for Chinese individuals, which may be different from the dosage used in other Asian populations. However, this study did not measure EPA levels or its metabolites. This is a limitation of the current work, which requires future work to explore the relationship between EPA levels and TG-lowering efficacy and cardiovascular risk reduction. The time of this study was short, and the study endpoints did not involve long-term follow-up and reduction of cardiovascular events, which is another limitation of this work. In addition, this study did not set up a comparison with other fatty acids, so there is still a lack of difference in the efficacy of EPA in reducing plasma TG level compared with other fatty acids. The cardiovascular benefits of EPA or other fatty acids may need to be further consolidated in a new randomized controlled study. In the future, more evidence is needed to further explore and compare the mechanism and efficacy of various fatty acids.